Disease Detail


Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org


  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")


  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
ALK I1171T Ceritinib ganglioneuroblastoma predicted - sensitive detail...
Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT01175356 Phase I Busulfan + Melphalan Cyclophosphamide + Topotecan 131I-MIBG Cyclophosphamide + Doxorubicin + Vincristine Sulfate Cisplatin + Etoposide Induction Therapy Including 131 I-MIBG and Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma Undergoing Stem Cell Transplant, Radiation Therapy, and Maintenance Therapy With Isotretinoin Active, not recruiting USA 0
NCT02095132 Phase Ib/II Adavosertib + Irinotecan Adavosertib and Irinotecan Hydrochloride in Treating Younger Patients With Relapsed or Refractory Solid Tumors Completed USA | CAN 0
NCT02311621 Phase I CE7R CAR T cells Engineered Neuroblastoma Cellular Immunotherapy (ENCIT)-01 Active, not recruiting USA 0
NCT02559778 Phase I Bortezomib Crizotinib Lapatinib Vorinostat Eflornithine Sorafenib Dasatinib Pediatric Precision Laboratory Advanced Neuroblastoma Therapy (PEDS-PLAN) Recruiting USA | CAN 0
NCT03332667 Phase I 131I-MIBG + Dinutuximab + Sargramostim + Vorinostat 131I-MIBG + Dinutuximab + Sargramostim MIBG With Dinutuximab +/- Vorinostat Active, not recruiting USA 0
NCT03721068 Phase I iC9.GD2.CAR.IL-15 T-cells Cyclophosphamide + Fludarabine Study of CAR T-Cells Targeting the GD2 With IL-15+iCaspase9 for Relapsed/Refractory Neuroblastoma Recruiting USA 0
NCT03786783 Phase II Isotretinoin Cyclophosphamide + Thiotepa Cisplatin + Dinutuximab + Etoposide + Sargramostim Cyclophosphamide + Dinutuximab + Doxorubicin + Sargramostim + Vincristine Sulfate Dexrazoxane Cyclophosphamide + Topotecan Dinutuximab + Isotretinoin + Sargramostim Carboplatin + Etoposide + Melphalan Dinutuximab, Sargramostim, and Combination Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma Active, not recruiting USA | AUS 1
NCT03794349 Phase II Dinutuximab + Irinotecan + Sargramostim + Temozolomide Dinutuximab + Eflornithine + Irinotecan + Sargramostim + Temozolomide Irinotecan Hydrochloride, Temozolomide, and Dinutuximab With or Without Eflornithine in Treating Patients With Relapsed or Refractory Neuroblastoma Recruiting USA | CAN | AUS 2
NCT04211675 Phase Ib/II Dinutuximab + Irinotecan + Sargramostim + Temozolomide NK Cells Infusions With Irinotecan, Temozolomide, and Dinutuximab (STING) Recruiting USA 0
NCT05421897 FDA approved Cyclophosphamide + Dinutuximab + Irinotecan + Sargramostim + Temozolomide + Topotecan Rapid Administration Pilot for Infusing Dinutuximab (RAPID) Recruiting USA 0
NCT05489887 Phase II Ceritinib + Naxitamab Naxitamab Naxitamab Added to Induction for Newly Diagnosed High-Risk Neuroblastoma Recruiting USA | CAN 0